What is Pfizer's ibrance — revenues:?

Pfizer (PFE) reported ibrance — revenues: of $1.01B in Q1 2026.

How has Pfizer's ibrance — revenues: changed year-over-year?

Pfizer's ibrance — revenues: increased by 3.2% year-over-year, from $977M to $1.01B.

What is the long-term trend for Pfizer's ibrance — revenues:?

Over 4 years (2021 to 2025), Pfizer's ibrance — revenues: has grown at a -6.7% compound annual growth rate (CAGR), from $5.44B to $4.12B.

What does ibrance — revenues: mean?

This metric represents the total gross sales generated by a specific oncology product line within the pharmaceutical portfolio. It reflects the market demand and commercial performance of a key therapeutic asset used in the treatment of specific cancer indications. Tracking this revenue stream is critical for assessing the lifecycle maturity and competitive positioning of the company's oncology franchise.

Pfizer PFE Ibrance — Revenues:

Other product segments

Eliquis

$2.17B+12.6%

Prevnar Family

$1.69B+1.8%

Vyndaqel family

$1.6B+7.8%

All Other Hospital and Biosimilars

$953M—

All other Primary Care

$654M+7.4%

Padcev

$591M+38.7%

All other Specialty Care

$579M+19.1%

Xtandi

$444M-3.1%

Oncology Biosimilars

$409M+54.9%

Royalty

$396M+28.6%

All other Oncology

$376M-0.3%

Nurtec ODT/Vydura

$353M+42.3%

Lorbrena

$305M+37.4%

Pfizer CentreOne

$289M+5.9%

Comirnaty

$232M-58.9%

Paxlovid

$219M-69.9%

Inlyta

$214M-2.3%

Sulperazon (Outside the U.S. and Canada)

$199M+21.3%

Adcetris

$190M-12.8%

Inflectra

$182M—

Abrysvo

$180M+37.4%

Xeljanz

$180M+40.6%

Braftovi/Mektovi

$174M+27.9%

Zavicefta (Outside the U.S. and Canada)

$150M+11.1%

Enbrel (Outside the U.S. and Canada)

$138M-1.4%

Bosulif

$129M-14.6%

Octagam

$122M—

Tukysa

$122M+19.6%

Zithromax

$112M-29.1%

Orgovyx

$109M—

Genotropin

$93M—

FSME-IMMUN/TicoVac

$81M—

Elrexfio

$80M+33.3%

Cibinqo

$76M+31.0%

Talzenna

$50M+25.0%

Tivdak

$33M0.0%

Similar metrics at other companies

ABBVImbruvica — Net revenues

$556M-24.7%

RFL

RFLProduct Revenue — Revenue

$89K-63.4%

ARDXIBSRELA — Total revenues

$70.07M+57.8%

JNJIMBRUVICA — Sales to customers (Note 9)

$660M-6.9%

BMRNBRINEURA — Total revenues

$47.1M+16.7%

OGNInt’l — Revenue

$1.1B+0.1%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$138.21B-3.7%

Enterprise value$200.88B-1.3%

P/E11.4×—

P/S2.2×-0.1×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's ibrance — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's ibrance — revenues:?: Pfizer (PFE) reported ibrance — revenues: of $1.01B in Q1 2026.
How has Pfizer's ibrance — revenues: changed year-over-year?: Pfizer's ibrance — revenues: increased by 3.2% year-over-year, from $977M to $1.01B.
What is the long-term trend for Pfizer's ibrance — revenues:?: Over 4 years (2021 to 2025), Pfizer's ibrance — revenues: has grown at a -6.7% compound annual growth rate (CAGR), from $5.44B to $4.12B.
What does ibrance — revenues: mean?: This metric represents the total gross sales generated by a specific oncology product line within the pharmaceutical portfolio. It reflects the market demand and commercial performance of a key therapeutic asset used in the treatment of specific cancer indications. Tracking this revenue stream is critical for assessing the lifecycle maturity and competitive positioning of the company's oncology franchise.